首页> 外文OA文献 >Safety and outcomes of endoscopic ultrasound-guided drainage for malignant biliary obstruction using cautery-enabled lumen-apposing metal stent
【2h】

Safety and outcomes of endoscopic ultrasound-guided drainage for malignant biliary obstruction using cautery-enabled lumen-apposing metal stent

机译:使用烧灼的腔浮管沉积金属支架对恶性胆道阻塞的内窥镜超声引导的安全性和结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and study aims There is increasing evidence to suggest that EUS-guided biliary drainage (EUS-BD) is a safe and effective treatment alternative for patients with malignant biliary obstructions (MBOs) after failed endoscopic retrograde cholangiopancreatography. Patients and methods We performed a retrospective analysis of data prospectively collected from patients with MBO who underwent choledochoduodenostomy (CDS) or gallbladder drainage (GBD) between August 2016 and June 2020 using the electrocautery-enabled lumen-apposing metal stents (ECE-LAMS). The primary endpoint was technical and clinical success. Secondary endpoints were adverse events (AEs) and reinterventions. Results A total of 60 patients were included in the study, with 56 CDS and 4 GBD. Median age was 76 years with 57 % male (34/60). The most common indication for EUS-BD was pancreatic cancer (78 %). Technical success was achieved in 100 % of cases, with a clinical success rate of 91.7 %. Mean total bilirubin pre-procedure was 202 umol/L (normal < 20 umol/L) and 63.8 umol/L post procedure (P  50 % reduction in bilirubin (mean bilirubin reduction 75 %). AEs occurred in 12 of 60 patients (20 %), all of which were mild. The reintervention rate was 11.7 % (7/60). Stent occlusion occurred in 10 of 60 patients (16.7 %) with a mean time to stent occlusion of 46.2 days (3–133). Stent patency of 83.3 % was observed with a mean follow up of 7.9 months. Conclusion EUS-CDS and GBD using ECE-LAMS are effective EUS-based techniques for managing patients with MBO. AEs are usually mild and resolved by reintervention.
机译:背景和学习旨在增加证据表明,令人毛肠引导胆道引流(EUS-BD)是对失败的内窥镜逆行胆管胆痴呆症后恶性胆道障碍物(MBOS)的安全有效的治疗方法。患者和方法我们对来自胆总管抑制术(CDS)或胆囊引流(GBD)的MBO患者进行了回顾性分析,这些数据在2016年8月和6月20日期间使用了一种能够的腔浮管(ECE-LAM)。主要终点是技术性和临床成功。次要终点是不良事件(AES)和重新融合。结果共有60名患者纳入研究,56℃,4 GBD。中位年龄为76岁,男性57%(34/60)。 EUS-BD最常见的指示是胰腺癌(78%)。技术成功在100%的情况下实现,临床成功率为91.7%。平均总胆红素预过程为202μmol/ l(正常<20μmol/ l)和63.8μmol/ l后术后(胆红素的p 50%(平均胆红素还原75%)。炎发生在60名患者中的12例(20名%),所有这些都是轻度。重复率为11.7%(7/60)。在60名患者中的10名(16.7%)中发生支架闭塞,平均闭塞46.2天(3-133)。支架观察到83.3%的平均后续6.9个月。结论EUS-CDS和GBD使用ECE-LAMS是有效的EUS基础技术,用于管理MBO患者。AES通常是温和的,并通过重新实施来解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号